Search
Back

Tapinarof

CAS 79338-84-4
Tapinarof

General Information

Tapinarof API is a novel, first-in-class, small molecule nonsteroidal, therapeutic aryl hydrocarbon receptor (AhR) agonist compound that acts as an anti-inflammatory and immunomodulatory agent. It is indicated for the treatment of plaque psoriasis in adults, in its finished dose. This novel therapeutic has also been shown to be effective for atopic dermatitis and is currently in phase 3 for this indication. Tapinarof works by regulating the activity of immune cells, reducing inflammation, and promoting the repair and regeneration of damaged skin cells. It received initial approval from the FDA in 2022.


About the API

Technology Synthetic
Therapeutic category Dermatology
Available formulations Topical / Dermatological
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.